The gut microbiome plays diverse roles in human health. Although Korean red ginseng (KRG) has shown therapeutic potential in animal models, its effects on the human gut microbiome after gastrointestinal (GI) cancer surgery remain underexplored. This prospective randomized controlled study aimed to evaluate postoperative safety of KRG and its impact on the gut microbiome and postoperative outcomes after GI cancer surgery. Patients were randomly assigned 1:1 to the red ginseng or control groups. Microbiome analysis of preoperative and postoperative fecal samples was performed using 16S rRNA sequencing. The alpha and beta diversities, taxonomic composition changes of microbiome, nutritional index, clinical symptoms, GI symptoms, and quality of life (QOL) were assessed. A total of 60 patients were enrolled and 16 patients in the red ginseng group and 25 in the control group were included in the final analysis. Postoperative alpha diversity decreased significantly in the control group, but remained relatively stable in the red ginseng group. Postoperative Lactobacillus levels increased significantly in the red ginseng group compared to the control group (18.34 % vs. 0.23 %; p < 0.001), whereas Bifidobacterium levels decreased (p = 0.002). Serum albumin levels were significantly higher in the red ginseng group at 3 months postoperatively (p = 0.003), and global health status/QOL scores were improved in the red ginseng group (p = 0.047). Red ginseng supplementation may play a protective role in gut microbiome, improving clinical outcomes in patients undergoing GI cancer surgery, as a safe and supportive therapy for enhancing postoperative recovery.
18 November 2025 in International Journal of Surgery
Background: Although mucinous cystic neoplasm (MCN) have a lower risk of high-grade dysplasia (HGD) or invasive carcinoma (IC) than branch duct type intraductal papillary mucinous neoplasm, aggressive surgical management is generally recommended. To optimize treatment strategies, the prevalence of HGD or IC in resected MCNs, as well as preoperative predictors, should be explored. These findings will inform patient selection for surgery and may reduce unnecessary interventions. Methods: This study systematically reviewed eligible studies that included information regarding the grade of dysplasia. Summary data, including carbohydrate antigen 19–9, cyst size, mural nodules, and cyst wall thickening, of patients with resected MCN were extracted and analyzed. Results: A total of 53 studies involving 4384 cases of resected MCN were selected in search of PubMed, Embase, and Cochrane databases. The pooled rate of HGD or IC among the resected MCN was 17.0%, with more recent studies showing a decreasing trend. Patients with HGD or IC had larger cysts than those with low-grade dysplasia ( P < 0.001). A cyst size threshold of 65 mm was identified as the optimal value for differentiating MCN with HGD or IC from those with low-grade dysplasia (Youden index: 0.44). Also, elevated carbohydrate antigen 19–9 (> 37 U/mL), the presence of mural nodules, and cyst wall thickening were associated with the diagnosis of HGD or IC. Conclusion: Given the low rates of HGD or IC in resected MCNs and the identification of specific preoperative risk factors, a more targeted surgical approach based on risk stratification is warranted.